Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 3/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | DAGLA | Q9Y4D2 | 4/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | DAGLB | Q8NCG7 | 2/20 | 0.36 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953171 | 0.93 | SERPINE1 (0.44) | SERPINE1CNR2DAGLAFFAR4FFAR1 | |
| SCHEMBL15434071 | 0.89 | SERPINE1 (0.45) | SERPINE1DAGLAFFAR4FFAR1MRGPRX4 | |
| SCHEMBL13580899 | 0.88 | SERPINE1 (0.42) | SERPINE1DAGLAFFAR4FFAR1MRGPRX4 | |
| SCHEMBL13580912 | 0.88 | SERPINE1 (0.42) | SERPINE1DAGLAFFAR4FFAR1MRGPRX4 | |
| SCHEMBL13580905 | 0.88 | SERPINE1 (0.43) | SERPINE1DAGLAFFAR4FFAR1MRGPRX4 | |
| SCHEMBL15434068 | 0.87 | SERPINE1 (0.48) | SERPINE1DAGLAFFAR4FFAR1MRGPRX4 | |
| SCHEMBL15434067 | 0.86 | SERPINE1 (0.48) | SERPINE1DAGLAFFAR4FFAR1MRGPRX4 | |
| SCHEMBL12952655 | 0.84 | SERPINE1 (0.60) | SERPINE1DAGLAFFAR4FFAR1MRGPRX4 | |
| SCHEMBL13580917 | 0.83 | FFAR4 (0.47) | SERPINE1DAGLAFFAR4FFAR1ABL1 | |
| SCHEMBL12952938 | 0.83 | SERPINE1 (0.59) | SERPINE1DAGLAFFAR4FFAR1DAGLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| WO-2009125606-A1 | PAI-1 INHIBITOR | 株式会社医薬分子設計研究所 (JP) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312315-A1 | PAI-1 INHIBITOR | SERPINC1, SERPINE1, SERPINH1 | SERPINE1 2/4885CNR2 3482/4885DAGLA 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.